DCVax®-L-Developed by Northwest Biotherapeutics|
Northwest Biotherapeutics, Inc. developed the DCVax®-L vaccine as an adjunct to the treatment of glioblastoma multiforme. In this review current data and perspectives of this product are examined. [Hum Vaccin Immunother] Full Article |
MicroRNA and Transcriptional Crosstalk in Myelinating Glia
The author focuses on the intersection of microRNAs with transcriptional regulation in Schwann cell and oligodendrocyte differentiation. In particular, several microRNAs have been shown to modulate expression of critical transcription factors, and in turn, the regulation of microRNA expression is enmeshed within transcriptional networks that coordinate both coding gene and noncoding RNA profiles of myelinating cells. [Neurochem Int] Abstract
Visit our reviews page to see a complete list of reviews in the neuroscience field.
Restoring Active Memory Program Poised to Launch|
Defense Advanced Research Projects Agency (DARPA) has selected two universities to initially lead the agency’s Restoring Active Memory program, which aims to develop and test wireless, implantable “neuroprosthetics” that can help servicemembers, veterans, and others overcome memory deficits incurred as a result of traumatic brain injury or disease. [DARPA] Press Release
NIH Funds Next Step of Cutting-Edge Research into Alzheimer’s Disease Genome
Teams of scientists will use support from the National Institutes of Health to conduct research into the genetic underpinnings of Alzheimer’s disease, analyzing how genome sequences – the order of chemical letters in a cell’s DNA – may contribute to increased risk or protect against the disease. The awards, expected to total $24 million over four years, go to eight academic medical centers that have been at the forefront of research in Alzheimer’s genetics. [National Institutes of Health (NIH)] Press Release
Q Therapeutics Announces First U.S. Patent Relating to Fifth Patent Family on Neural Cells
Q Therapeutics, Inc. announced that the United States Patent and Trademark Office has issued the company the first U.S. patent from its fifth patent family on neural cells. U.S. Patent No. 8,673,292, titled “Pure Populations of Astrocyte Restricted Precursor Cells and Methods for Isolation and Use Thereof,” covers the astrocyte family of neural cells of the central nervous system. [Q Therapeutics, Inc.] Press Release
From our sponsor:
Looking for ALDH+ cancer stem cells? Watch a video to see how ALDEFLUOR™ can help.